KPV Oral Capsules 500mcg

KPV acts through melanocortin receptor 1 (MC1R) and through direct intracellular mechanisms in epithelial cells. It suppresses NF-kB nuclear translocation -- a critical step in the inflammatory signaling cascade -- and downstream production of pro-inflammatory cytokines including IL-6, IL-8, and TNF-alpha. In intestinal epithelial cell studies, KPV has been shown to reduce inflammatory cytokine production induced by bacterial components (LPS) and by cytokines like IL-1beta. The MC1R-mediated component adds an additional layer of anti-inflammatory signaling through cAMP pathway activation.

KPV's intestinal epithelial cell activity and potential oral stability make it particularly suited for GI inflammatory research. IBD (Crohn's disease, ulcerative colitis) involves inflammatory activation of intestinal mucosal cells, and local delivery of anti-inflammatory signals to these cells is a therapeutic goal. KPV's small size (tripeptide) gives it better potential for surviving GI transit than larger peptides, though stability is still formulation-dependent. Nanoparticle formulations for oral KPV delivery to the intestinal mucosa have been developed and studied in colitis models specifically for this reason.

Full alpha-MSH (13 amino acids) activates all five melanocortin receptors (MC1R-MC5R) including MC4R, which mediates appetite suppression and sexual effects in the hypothalamus. KPV retains the anti-inflammatory C-terminal activity with more selective receptor engagement and much smaller molecular size. For research specifically on the anti-inflammatory arm of alpha-MSH activity without confounding appetite/endocrine effects, KPV is a more tractable tool. The small size also makes it more amenable to oral delivery research for GI applications.